科技赋能中华老字号：东阿阿胶的创新破局之路

Core Viewpoint - Dong'e Ejiao is leveraging technological innovation to reshape the competitiveness of the Ejiao industry, aiming for breakthroughs in research and development by 2025, which includes revising the standards for Ejiao slices in the Chinese Pharmacopoeia and publishing original research in international journals [1][9]. Group 1: Technological Innovation and Strategic Planning - The company has initiated a systematic approach to technological innovation, highlighted by the "14th Five-Year" R&D strategic seminars and the first Technology Innovation Conference, which set clear directions for future growth [2]. - The conference gathered top scholars and academicians to focus on the dual business layout of pharmaceutical and health consumer products, establishing a top-level design for R&D [2]. - Dong'e Ejiao has formed the "Qi and Blood Theory Research Innovation Alliance" with eight institutions to integrate traditional theories with modern evidence, providing a scientific basis for product development [3]. Group 2: Platform Construction and Research Achievements - The company is building an innovation engine through a model of "One Center, Three High Grounds + N Collaborations," with the National Engineering Research Center for Gelatin Chinese Medicine as the core platform [3]. - Significant research achievements include the discovery of active peptides in Ejiao and the establishment of exclusive testing methods, which have been published in high-impact journals [3]. - Collaborations with universities and research institutes have led to the development of 15 new health products, enhancing the convenience and marketability of traditional supplements [3][4]. Group 3: Mechanism Reform and Market Performance - Dong'e Ejiao has reformed its mechanisms to create a closed-loop ecosystem of "talent-incentive-transformation," enhancing innovation efficiency [5]. - The company has implemented a stock incentive plan covering 25% of core R&D personnel and a milestone reward system to align talent value with long-term corporate development [6]. - In the first three quarters of 2025, the company achieved a revenue of 4.766 billion yuan, a year-on-year increase of 10.10%, and a net profit of 1.274 billion yuan, reflecting robust business growth despite industry pressures [7]. Group 4: Product Development and Market Strategy - The company is focusing on a "big variety strategy" to convert technological advantages into market benefits, with the compound Ejiao syrup being a flagship product [8]. - Research on the compound Ejiao syrup has received accolades, including an award at the 2025 ASCO annual meeting, validating its clinical value [8]. - Technological advancements in the deer industry and the successful approval of production licenses for new products are expected to inject new vitality into the brand [8]. Group 5: Future Outlook and Global Expansion - Dong'e Ejiao is exploring a high-quality development path that integrates traditional medicine with modern technology and global markets [9]. - The company aims to deepen research on Qi and Blood Theory, promote smart manufacturing technologies, and advance internationalization efforts [9].